Reaction
Immune-Mediated Nephritis reporting signals
As of the last recalculation, Immune-Mediated Nephritis appears in 447 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 140.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ipilimumab | 101 | 140.5 | 140.8 |
| Pembrolizumab | 180 | 132.7 | 132.9 |
| Durvalumab | 50 | 128.7 | 129.0 |
| Nivolumab | 154 | 112.6 | 112.8 |
| Fluticasone Furoate | 25 | 101.7 | 101.9 |
| Pemetrexed | 22 | 50.2 | 50.2 |
| Carboplatin | 105 | 50.0 | 50.0 |
| Pemetrexed Disodium | 28 | 36.4 | 36.5 |
| Paclitaxel (Aibumin-Bound) | 44 | 27.5 | 27.6 |
| Axitinib | 10 | 24.4 | 24.4 |
| Paclitaxel | 46 | 24.0 | 24.0 |
| Lenvatinib | 16 | 23.5 | 23.5 |
| Atezolizumab | 16 | 19.9 | 19.9 |
| Encorafenib | 4 | 19.0 | 19.0 |